aTyr Pharma Inc. Class Action Lawsuit - ATYR
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The aTyr Pharma class action lawsuit seeks to represent purchasers or acquirers of aTyr Pharma Inc. (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). Captioned Munguia v. aTyr Pharma Inc., No. 25-cv-02681 (S.D. Cal.), the aTyr Pharma class action lawsuit charges aTyr Pharma and aTyr Pharma’s CEO with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the aTyr Pharma class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the aTyr Pharma class action lawsuit must be filed with the court no later than December 8, 2025.
CASE ALLEGATIONS: aTyr Pharma is a clinical stage biotechnology company that engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
The aTyr Pharma class action lawsuit alleges that defendants concealed material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage.
The aTyr Pharma class action lawsuit further alleges that on September 15, 2025, aTyr Pharma hosted an investor call announcing that the EFZO-FIT study did not meet its primary endpoint. In pertinent part, according to the complaint, defendants announced that the study did not meet its primary endpoint in change from baseline in mean daily OCS dose at week 48 and that aTyr Pharma’s next step was to engage with the U.S. Food and Drug Administration to determine a path forward, given the disappointing topline results. On this news, the price of aTyr Pharma common stock fell more than 83%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired aTyr Pharma common stock during the Class Period to seek appointment as lead plaintiff in the aTyr Pharma class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the aTyr Pharma class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the aTyr Pharma class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the aTyr Pharma class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.